Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide

A method of inhibiting the formation of crystals in a pharmaceutical composition containing (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide represented by Formula (1)

• comprising:
• dissolving the compound of Formula (1) in a solvent that ensures a solubility of the compound of Formula (1) in the solvent is 100 mg/mL or more to obtain a first solution;
• dissolving a cellulosic polymer in water to obtain a second solution;
• adding the first solution dropwise to the second solution thereby obtaining a mixed solution,
• wherein the cellulosic polymer is hypromellose, and
• wherein the cellulosic polymer has a viscosity of 2 to 10 mPa·s, a content of 1 to 5 wt. % of the total weight of the composition, and a weight ratio of 1:1 to 3:1 relative to the compound represented by Formula (1).